Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 7
Submit an article Journal homepage
171
Views
54
CrossRef citations to date
0
Altmetric
Miscellaneous

Bosentan: a dual endothelin receptor antagonist

Sébastien Roux Actelion Ltd., Allschwil, Switzerland, Division of Pulmonary & Critical Care Medicine, Department of Medicine, University of California at San Diego, School of Medicine, 9300 Campus Point Drive, 7372, La Jolla, CA 92037, USA, Tel: +1 858 657 7105;, E-mail: [email protected]
&
Lewis J Rubin Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California at San Diego School of Medicine, La Jolla, CA, USA
Pages 991-1002 | Published online: 24 Feb 2005

Bibliography

  • HAYNES WG, WEBB DJ: The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin. Sci. (1993) 84:485–500.
  • LEVIN ER: Endothelins. N Engl. I Med. (1995) 333:356–363.
  • ••Comprehensive review of endothelins and their role in health and disease.
  • HIRATA Y, EMORI T, EGUCHI S et al:Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. Clin. Invest. (1993) 91:1367–1373.
  • FILEP JG, HERMAN F, BATTISTINI B, CHABRIER P-E, BRAQUET P, SIROIS P: Antiaggretory and hypotensive effects of endothelin-1 in beagle dogs: role for prostacyclin. Cardiovasc. Pharrnacol. (1991) 17\(Suppl. 7):S216–S218.
  • CANNAN CR, BURNETT Jr JC, LERMAN A: Enhanced coronary vasoconstriction to endothelin-B receptor activation in experimental congestive heart failure. Circulation (1996) 93:646–651.
  • CARDILLO C, KILCOYNE CM, WACLAWIW M, CANNON III RO, PANZA JA: Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension (1999) 33:753–758.
  • ABRAHAM DJ, VANCHEESWARAN R, DASHWOOD MR et al.: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. (1997) 151:831–841.
  • •A study on the distribution and expression levels of ET and ET receptors in sderoderma-associated lung disease.
  • BAUER M, WILKENS H, LANGER F, SCHNEIDER SO, LAUSBERG H, SCHAFERS H-J: Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation (2002) 105:1034–1036.
  • LAUTH M, BERGER M-M, CATTARUZZA M, HECKER M: Elevated perfusion pressure upregulates endothelin-1 and endothelin B receptor expression in the rabbit carotid artery. Hypertension (2000) 35:648–654.
  • YOKOYAMA Y, BAVEJA R, SONIN N, NAKANISHI K, ZHANG JX, CLEMENS MG: Altered endothelin receptor subtype expression in hepatic injury after ischemia/ reperfusion. Shock (2000) 13:72–78.
  • FUKURODA T, FUJIKAWA T, OZAKI S, ISHIKAWA K, YANO M, NISHIKIBE M: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem. Biophys. Res. Commun. (1994) 199:1461–1465.
  • ITO H, HIRATA Y, HIROE M et al: Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circulation (1991) 69:209–215.
  • PEACOCK AJ, DAWES KE, SHOCK A, GRAY AJ, REEVES JT, LAURENT GJ: Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am. f Respic Cell Mol Biol. (1992) 7:492–499.
  • PIACENTINI L, GRAY M, HONBO NY, CHENTOUFI J, BERGMAN M, KARLINER JS: Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase Cf Mol Cell Cardiol (2000) 32:565–576.
  • DAVIE N, HALEEN SJ, UPTON PD et al: ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. f Respir: Crit. Care Med. (2002) 165:398–405.
  • TEDER P, NOBLE PW: A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am. J. Respir. Cell Ma Biol. (2000) 23:7–10.
  • ROSSI GP, ALBERTIN G, NERI G et al: Endothelin-1 stimulates steroid secretion of human adrenocortical cells ex vivo via both ETA and ETB receptor subtypes. I Clin. Endocrinol Metab. (1997) 82:3445–3449.
  • SOTSCH G, BERTEL 0, RICKENBACHER P et al.: Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am. Cardiol (2000) 85:973–976.
  • GIAID A, YANAGISAWA M, LANGLEBEN D et al: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl. I Med. (1993) 328:1732–1739.
  • •Presents histological evidence for ET-1 in pulmonary hypertension.
  • VEYSSIER-BELOT C, CACOUB P: Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc. Res. (1999) 44:274–282.
  • •Review of the molecular factors involved in the pathophysiology of pulmonary hypertension and implications for its management.
  • MIYAUCHI T, YORIKANE R, SAKAI S et al.: Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ. Res. (1993) 73:887–897.
  • STELZNER TJ, O'BRIEN RE YANAGISAWA M et al.: Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am. Physiol (1992) 262:L614–L620.
  • CACOUB P, DORENT R, NATAF P et al: Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc. Res. (1997) 33:196–200.
  • YOSHIBAYASHI M, NISHIOKA K, NAKAO K et al.: Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary circulation. Circulation (1991) 84:2280–2285.
  • RUBIN U. ACCP consensus statement: primary pulmonary hypertension. Chest (1993) 104:236–250.
  • ABENHAIM L, MORIDE Y, BRENOT F et al.: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl. Med. (1996) 335:609–616.
  • GAINE SP, RUBIN LJ: Primary pulmonary hypertension. Lancet (1998) 352:719–725.
  • •Comprehensive review of primary pulmonary hypertension.
  • RUBIN LJ: Primary pulmonary hypertension. N Engl. I Med. (1997) 336:111–117.
  • •Overview of the current understanding of primary pulmonary hypertension.
  • RICH S, DANTZKER DR, AYERS SM et al: Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. (1987) 107:216–223.
  • D'ALONZO GE, BARST RJ, AYRES SM et al.: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med. (1991) 115:343–349.
  • •Large evaluation of the survival rates and factors associated with survival in patients with primary pulmonary hypertension.
  • OAKLEY CW: Primary pulmonary hypertension: case series from the United Kingdom. Chest (1994) 105(Suppl.):295-32S.
  • KOH ET, LEE P, GLADMAN DD, ABU-SHAKRA M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br. Rheumatol (1996) 35:989–993.
  • STUPI AM, STEEN VD, OWENS GR, BARNES EL, RODNAN GP, MEDSGER Jr TA: Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritic Rheum. (1986) 29:515–524.
  • SHAPIRO SM, OUDIZ RJ, CAO T et al:Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. I Am. Coll. Cardiol (1997) 30:343–349.
  • THE INTERNATIONAL PPH CONSORTIUM, LANE KB, MACHADO RD et al.: Heterozygous germline mutations in BMPR2, encoding a TGF-B receptor, cause familial primary pulmonary hypertension. Nat. Genet. (2000) 26:81–84.
  • THOMSON JR, MACHADO RD, PAUCIULO MW et al.: Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-B family. Med. Genet. (2000) 37:741–745.
  • RICH S, KAUFMANN E, LEVY PS: Theeffect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl. I Med. (1992) 327:76–81.
  • SITBON 0, HUMBERT M, JAGOT J-Let al.: Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Ear: Respic (1998) 12:265–270.
  • RICH S, BRUNDAGE B: High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation (1987) 76:135–141.
  • BADESCH DB, TAPSON VF, MCGOON MD et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann. Intern. Med. (2000) 132:425–434.
  • BARST RJ, RUBIN LJ, LONG WA et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl. I Med. (1996) 334:296–301.
  • BARST RJ, RUBIN LJ, MCGOON MD et al.: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. (1994) 121:409–415.
  • WANSTALL JC, JEFFERY TK: Recognition and management of pulmonary hypertension. Drugs (1998) 56:989–1007.
  • GARDINER SM, KEMP PA, MARCH JE, BENNETT T: Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br. Pharmacol (1994) 112:823–830.
  • CARRATU P, SCURI M, STYBLO JL, WANNER A, GLASSBERG MK: ET-1 induces mitogenesis in ovine airway smooth muscle cells via ETA and ETBreceptors. Am. Physiol. (1997) 272:L1021–L1024.
  • KATWA LC, GUARDA E, WEBER KT: Endothelin receptors in cultured rat cardiac fibroblasts. Cardiovasc. Res. (1993) 27:2125–2129.
  • MCCULLOCH KM, DOCHERTY CC, MORECROFT I, MACLEAN MR: Endotheling receptor-mediated contraction in human pulmonary resistance arteries. Br..! Pharmacol (1996) 119:1125–1130.
  • CLOZEL M, BREU V, GRAY GA et al.: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. Pharmacol Exp. The]: (1994) 270:228–235.
  • ••Original pharmacological characterisationof bosentan.
  • ROUX S, BREU V, ERTEL SI, CLOZEL M: Endothelin antagonism with bosentan: a review of potential applications. J. MM. Med. (1999) 77:364–376.
  • CHAMPION HC, ESTRADA LS, ESTRADA LN, FILEP JG, KADOWITZ PJ: Analysis of effects of bosentan (Ro 47-0203), a nonpeptide endothelin ETA/ETB receptor antagonist, in the hind-limb vascular bed of the cat. Can. Physiol Pharmacol (1998) 76:141–147.
  • DOMKOWSKI PW, COCKERHAM JT, KOT PA, MYERS JL, HOPKINS RA: Characterization of the pulmonary arterial response to endothelin-1 and bosentan in neonatal pigs. Ann. Thome. Surg. (2000) 70:1522–1530.
  • MARTIN C, HELD HD, UHLIG S: Differential effects of the mixed ET(A)/ ET(B)-receptor antagonist bosentan on endothelin-induced bronchoconstriction, vasoconstriction and prostacyclin release. Naunyn Schmiedebergs Arch. Pharmacol (2000) 362:128–136.
  • ROSSI GP, SACCHETTO A, RIZZONI D et al.: Blockade of angiotensin II Type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arteriosc/er. Thromb. V3SC. Bid (2000) 20:949–956.
  • HESS P, CLOZEL M, CLOZEL J-P: Telemetry monitoring of pulmonary arterial pressure in freely moving rats.' Appl. Physiol (1996) 81:1027–1032.
  • CHEN S-J, CHEN Y-F, MENG QC, DURAND J, DICARLO VS, OPARIL S: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. Appl Physiol (1995) 79:2122–2131.
  • EDDAHIBI S, RAFFESTIN B, CLOZEL M, LEVAME M, ADNOT S: Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am. Physiol (1995) 268:H828–H835.
  • HOLM P, LISKA J, CLOZEL M, FRANCO-CERECEDA A: The endothelin antagonist bosentan: hemodynamic effects during normwda and hypoxic pulmonary hypertension in pigs.' Thome. Cardiovasc. Surg. (1996) 112:890–897.
  • WANECEK M, OLDNER A, RUDEHILL A, SOLLEVI A, ALVING K, WEITZBERG E: Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan. Shock (1997) 7:364–370.
  • KIM H, YUNG GL, MARSH JJ et al: Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Ear. Respir. (2000) 15:640–648.
  • PARK S-H, SALEH D, GIAID A, MICHEL RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. Resp. Grit. Care Med (1997) 156:600–608.
  • ••Study of the role of ET and bosentan in arodent model of pulmonary fibrosis.
  • MULDER P, RICHARD V, DERUMEAUX G et al.: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation (1997) 96:1976–1982.
  • MISHIMA T, TANIMURA M, SUZUKI G et al.: Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. Am. Coll. Cardiol (2000) 35:222–229.
  • HERBERT KJ, HICKEY MJ, LEPORE DA, KNIGHT KR, MORRISON WA, STEWART AG: Effects of the endothelin receptor antagonist bosentan on ischaemia/ reperfusion injury in rat skeletal muscle. Ear: Pharmacol (2001) 424:59–67.
  • FILEP JG, FOURNIER A, FOLDES-FILEP È: Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors. Br. Pharmacol (1995) 115:227–236.
  • GUIMARAES CL, DA SILVA S, COUTURE R, RAE GA: Mixed endothelin ET(A) and ET(B) antagonist bosentan inhibits oleic acid-induced lung plasma extravasation in mouse.' Cardiovasc. Pharmacol (2000) 36(5, Suppl. 1):S371–S373.
  • BRANDLI P, LOFFLER B-M, BREU V, OSTERWALDER R, MAIRE J-P, CLOZEL M: Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain (1995) 64:315–322.
  • KIOWSKI W, SOTSCH G, HUNZIKER P et al.: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 346:732–736.
  • SOTSCH G, KIOWSKI W, YAN X-W et al.: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation (1998) 98:2262–2268.
  • WEBER C, GASSER R, HOPFGARTNER G: Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metabol Dispos. (1999) 27:810–815.
  • WEBER C, SCHMITT R, BIRNBOECK H et al.: Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. Clin. Pharmacol (1999) 39:703–714.
  • WEBER C, SCHMITT R, BIRNBOECK H et al.: Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol Thec (1996) 60:124–137.
  • WEBER C, BANKEN L, BIRNBOECK H, SCHULZ R: Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. Clin. Pharmacol (1999) 39:847–854.
  • WEBER C, BANKEN L, BIRNBOECK H, NAVE S, SCHULZ R: The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br. Clin. Pharmacol (1999) 47:701–706.
  • VAN GIERSBERGEN PLM, CLOZEL M, BODIN F: A drug interaction study between bosentan and ketoconazole and losartan. [Abstract] Clin. Pharmacol Ther. (2001) 69:P67.
  • DINGEMANSE J, BODIN F, WEIDEKAMM E, KUTZ K, VAN GIERSBERGEN P: Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacol (2002) 42:283–289.
  • CHANNICK RN, SIMONNEAU G, SITBON 0 et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 358:1119–1123.
  • ••Report of the first study of an ERA in patients with pulmonary hypertension.
  • RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl. I Med. (2002) 346:896–903.
  • ••Report of the pivotal double-blind, placebo-controlled trial of bosentan in patients with pulmonary hypertension.
  • PACKER M, CASPI A, CHARLON V et al: Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure — results of the REACH-1 trial. Circulation (1998) 98(Suppl.):I–3.
  • PACKER M. Effects of the endothelin receptor antagonist bosentan on the morbidity and mortality in patients with chronic heart failure: results of the ENABLE 1 and 2 trial program. American College of Cardiology 51st Annual Scientific Session, Atlanta, GA. March 19, 2002.
  • KRUM H, CHARLON V, WIDMANN T, PACKER M: Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure. [Abstract] Circulation (1999) 100\(Suppl. 41646.
  • MYLONA P, CLELAND JGF, on behalf of the CARDIO.NET EDITORIAL TEAM: Update of REACH-1 and MERIT-HF clinical trials in heart failure. Ear: I Heart Failure (1999) 1:197–200.
  • BELCH JJF: Raynaud's phenomenon. CurcOpin. Rheumatol (1989) 1:490–498.
  • TAMAKI T, MORI S, TAKEHARA K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch. Dermatol Res. (1991) 283:366–371.

Websites

  • http://www.who.int/ncd/cvd/pph.html Executive summary from the World Symposium on Primary Pulmonary Hypertension (1998).
  • •Overview of the current understanding of primary pulmonary hypertension.
  • http://www.pha-uk.com/info-whatisit.htm Pulmonary Hypertension Association (UK) website, What Is It? (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.